JP2001522783A5 - - Google Patents

Download PDF

Info

Publication number
JP2001522783A5
JP2001522783A5 JP2000516701A JP2000516701A JP2001522783A5 JP 2001522783 A5 JP2001522783 A5 JP 2001522783A5 JP 2000516701 A JP2000516701 A JP 2000516701A JP 2000516701 A JP2000516701 A JP 2000516701A JP 2001522783 A5 JP2001522783 A5 JP 2001522783A5
Authority
JP
Japan
Prior art keywords
botulinum toxin
modified botulinum
modified
glu
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000516701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001522783A (ja
Filing date
Publication date
Priority claimed from US08/954,302 external-priority patent/US6051239A/en
Application filed filed Critical
Publication of JP2001522783A publication Critical patent/JP2001522783A/ja
Publication of JP2001522783A5 publication Critical patent/JP2001522783A5/ja
Pending legal-status Critical Current

Links

JP2000516701A 1997-10-20 1998-10-16 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法 Pending JP2001522783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US08/954,302 1997-10-20
PCT/US1998/021897 WO1999020306A1 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Publications (2)

Publication Number Publication Date
JP2001522783A JP2001522783A (ja) 2001-11-20
JP2001522783A5 true JP2001522783A5 (https=) 2006-02-16

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000516701A Pending JP2001522783A (ja) 1997-10-20 1998-10-16 経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法

Country Status (16)

Country Link
US (1) US6051239A (https=)
EP (1) EP1024827B1 (https=)
JP (1) JP2001522783A (https=)
KR (1) KR100594787B1 (https=)
CN (1) CN1246038C (https=)
AT (1) ATE355076T1 (https=)
AU (1) AU756475B2 (https=)
BR (1) BR9815255A (https=)
CA (1) CA2306995A1 (https=)
DE (1) DE69837209T2 (https=)
EE (1) EE200000536A (https=)
HU (1) HUP0101017A3 (https=)
IL (1) IL135743A (https=)
NZ (1) NZ504549A (https=)
RU (1) RU2227042C2 (https=)
WO (1) WO1999020306A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
ATE519494T1 (de) * 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
DE60130266D1 (de) * 2000-11-06 2007-10-11 Us Army Med Res Mat Command Rekombinante leichte kette des botolinum neurotoxins and fusionsproteine davon zur verwendung in forschung und klinischer therapie
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004044161A2 (en) 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
CA2510058C (en) * 2002-12-20 2010-03-16 Botulinum Toxin Research Associates, Inc. Improved pharmaceutical botulinum toxin compositions
EP1594956A4 (en) * 2003-02-03 2007-08-01 Fraunhofer Usa Inc SYSTEM FOR EXPRESSION OF GENES IN PLANTS
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
AU2005216133A1 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa, Inc. Systems and methods for clonal expression in plants
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
JP4994241B2 (ja) * 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
PH12011502633A1 (en) 2005-10-07 2012-11-12 Zoetis P Llc Vaccines and methods to treat canine influenza
EP2155883A1 (en) * 2007-05-30 2010-02-24 Wyeth LLC Raccoon poxvirus expressing genes of feline antigens
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
US20190185837A1 (en) 2017-12-20 2019-06-20 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
AU6326896A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Chemically-modified clostridiatoxin with improved properties

Similar Documents

Publication Publication Date Title
JP2001522783A5 (https=)
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
ID30171A (id) Kombinasi formoterol dan mometason furoat untuk asma
CA2288143A1 (en) Activated protein c formulations
WO1996020734A3 (en) Oral gastrointestinal x-ray contrast agents in combination with pharmaceutically acceptable clays and surfactants
HRP20030951B1 (hr) Formulacije jednodnevnih doza oksikodona
HRP20020088B1 (hr) Levodopa/karbidopa/entakapon farmaceutski pripravak
AU4425496A (en) Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
JP2002528502A5 (https=)
JP2005508338A5 (https=)
SE8801732L (sv) Ny komposition
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
JP2002522501A5 (https=)
CA2032475A1 (en) Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
HU9302970D0 (en) Swallowable prepartions for the treatment of pains of superior gastrointestinal tracts
EP1431286A3 (en) Prodigiosin derivatives for treating cancer or viral diseases
JP2003514025A5 (https=)
NO20042011L (no) Fremgangsmate ved fremstilling av en farmasoytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom
ES2286471T3 (es) Composiciones farmaceuticas antivirales.
EG24584A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of uicerative colitis and crohn's disease
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
JP2002326936A5 (https=)
SE0001916D0 (sv) Novel formulation
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient